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Abstract
Cerebrovascular disease is currently the second most common cause of death after ischemic heart disease. In this
article, we mainly focus on the application of permeability imaging in cases of ischemic and hemorrhagic stroke,
and cerebral small vessel disease. In this review, we discuss the application of permeability imaging in ischemic
stroke from two aspects: 1) for the prediction of hemorrhagic transformation after infarction, and 2) for the
evaluation of newborn secondary and tertiary collateral circulations. Quantitative measurements of blood–brain
barrier (BBB) disruption by the Dynamic Contrast Enhance MR (DCE-MR) can reveal the severity of intracranial
hemorrhage (ICH)-induced brain damage, and that the technique has the potential to be used for testing the
efficacy of interventions aimed at reducing tissue damage around the hematoma. Currently, DCE-MR is mostly
applied for the assessment of tumors in patients. There is less research focused on the evaluation of mild BBB
defects in normal or abnormal aging brains, dementia, or cerebral small vessel disease. More work needs to be
done to select the appropriate contrast agents and decide their doses, as well as to identify methods for parameter
collection and data analysis.
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Background
Cerebrovascular disease is currently the second most
common cause of death after ischemic heart disease, and
a leading cause of disability [1]. Every year, 15 million
people worldwide experience ischemic or hemorrhagic
stroke [2]. Modern imaging techniques not only clarify
the nature of the stroke within minutes, but also play
critical roles in identifying the cause of the stroke, guid-
ing the late-stage treatment, and evaluating the progno-
sis [2]. Large numbers of molecular imaging techniques,
including permeability imaging, have gradually entered
clinical practice, and help physicians who are involved in
neurosurgery and neuroimaging, gain a deeper under-
standing of the pathophysiological changes in nervous
system disorders.
Permeability imaging is often used in the diagnosis
and prognosis of brain tumors, as well as in the blood–
brain barrier permeability (BBBP) assessment for ische-
mic cerebrovascular disease, spontaneous intracerebral
hemorrhage (ICH), cerebral small vessel disease, cogni-
tive dysfunction, multiple sclerosis, and brain trauma
[3–6]. In this article, we mainly focus on the application
of permeability imaging in cases of ischemic and
hemorrhagic stroke, and cerebral small vessel disease.
Review
Neurovascular unit, BBB, and BBB permeability
The process of tissue damage after stroke is highly com-
plex, involving changes in brain vasculature and paren-
chyma that are regulated by the interactions of a variety of
mechanisms. More and more studies suggest that the
treatment of cerebrovascular diseases must go beyond the
concept of cell damage alone. It is important to pay more
attention to the dynamic changes in the neurovascular
units (NVU), which are the integrative microunits of
structure and function of the nervous system. Thus, neu-
rons, endothelial cells, astrocytes, and the extracellular
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matrix that maintains the integrity of the brain tissue need
to be viewed comprehensively, with the BBB acting as the
core of the NVU [7]. The negative results from clinical tri-
als of neuro-protective drugs also support this idea, mak-
ing the NVU an important therapeutic target in future
clinical research. The extent of damage and the late-stage
recovery of the NVU determine the clinical outcome of
patients. However, no ideal method can assess NVU dys-
function accurately or quantitatively.
Some researchers quantify the damage to the NVU by
examining specific markers, such as Matrix Metallopro-
teinases (MMPs), Vascular Endothelial Growth Factor
(VEGF), Platelet Derived Growth Factor (PDGF), and
Fibroblast Growth Factor (FGF), in blood or cerebro-
spinal fluid [8]. However, the specificity of this method
is low, spatially, as it cannot distinguish the location and
the extent of NVU damage in different brain regions.
Double-photon laser-scanning microscopy, which can
detect the dynamic relationship between the microvas-
culature and the surrounding structure in living tissue, is
the ideal imaging method for examining the NVU. How-
ever, due to the complicated scanning procedure in-
volved and the need for a craniotomy in order to expose
the areas of interest, Double-photon microscopy is cur-
rently used only in animal models [9].
The BBB, which is composed of capillary endothelial
cells, basement membrane, pericytes located outside the
basement membrane, and the perivascular end-feet of
astrocytes, is the most important protective structure in
the brain. It can reduce the passive movement of water
molecules and restrict the passage of soluble substances
from the blood, thereby preventing brain cells from be-
ing exposed to neurotoxins or other harmful blood-
borne substances. The BBB is considered as the core
structure of the NVU, and the defects in structure and
function can be found in most neurological diseases.
Disorders of the BBB are particularly evident in ische-
mic cerebrovascular disease, and show dynamic changes
under different states of tissue damage and reperfusion.
After ischemic brain damage, BBB leakage occurs not
only during the acute and subacute phases of stroke
[10], but also at the early stage of angiogenesis during
stroke recovery [11]. In addition, studies have found that
BBB disruption is most significant at the edges of the
hematoma, 1 week after spontaneous ICH, and quantita-
tive measurement of the BBB damage can reflect the ex-
tent of ICH-induced brain damage. Damage to the BBB
can also be found in the early stage of lacunar infarction,
white matter osteoporosis, and other cerebral small ves-
sel diseases [12].
The severity of BBB damage is positively correlated
with the degree of brain tissue damage or hypoxia and
ischemia, and therefore quantitative assessment of the
disruption of the BBB (i.e., the BBBP) can be used for
quantitative evaluation of the severity of the NVU dam-
age [13].
Principles of permeability imaging
Permeability imaging uses classic pharmacokinetic the-
ory to quantitatively assess the rate at which a contrast
agent passes through the BBB [14]. The increase in
BBBP reflects BBB-relevant pathophysiological changes,
and therefore the quantitative description of the BBBP
has important clinical significance [15]. Common pa-
rameters include volume transfer constant (Ktrans) and
permeability-surface area product (PS). Between the two,
Ktrans is generally believed to represent permeability.
Though there are multiple methods to obtain perme-
ability parameters, such as first pass data of perfusion
CT and Dynamic Susceptibility Contrast MR, the stand-
ard method for BBB permeability assessments are based
on Dynamic contrast-enhanced MR (DCE-MR). The
DCE-MR scanning process begins with multiple flip-
angle T1 sequences, followed by intravenous injection of
contrast agent, after which the T1-weighted GRE se-
quence is acquired over several minutes. The observa-
tion of a linear relationship between the MR signal
intensity and the scan time indicates that the slope is as-
sociated with BBB permeability [2]. In patients with sub-
sequent hemorrhagic transformation (HT), even an
enhanced T1 sequence does not exhibit a visually identi-
fiable enhanced effect. However, the increase in BBB
permeability at this stage can be observed in DCE-MR
[16]. Studies have indicated that the DCE acquisition
time should be at least 210 s [17] in order to distinguish
between patients with HT from those without HT.
Currently, the tracer kinetics model used in most per-
meability imaging is the corrected single-capillary model
proposed by Larsson and Tofts [18, 19]. However, this
model requires hemodynamic balance, which calls for
relatively long scan times. The Patlak model [20] only
analyzes the first-pass data of the contrast agent. Requir-
ing lesser amounts of data, it has been successfully used
to analyze permeability data and obtain relevant parame-
ters such as Ktrans. Multiple studies using Patlak data
analysis have correctly assessed the permeability param-
eter Ktrans in stroke patients [21]. However, this ap-
proach can only be used in cases with moderate BBB
leakage. When there is severe BBB leakage, data collec-
tion takes a longer time and the results are biased.
In the future, quantitative assessment of BBB leakage
needs to mainly focus on reducing errors, particularly on
optimizing the assessment of arterial input function to
reduce errors caused by different tracers.
Application in ischemic brain injury
The defect of BBB occurs rapidly after acute cerebral in-
farction and is accompanied by a significant increase in
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BBBP. Studies have shown that the average time to BBB
defect after the onset of cerebral ischemia is 3.8 h, which
is similar to the time at which irreversible brain damage
occurs [13].
Here, we discuss the application of permeability im-
aging in two aspects: 1) for the prediction of HT after in-
farction, and 2) for the evaluation of newborn secondary
and tertiary collateral circulations.
Symptomatic HT is one of the most serious complica-
tions of acute ischemic stroke and is closely related to
clinical outcomes [22]. Currently, the commonly used
imaging techniques cannot directly assess the risk of
HT. A number of studies have demonstrated that en-
hanced MR is highly capable of predicting HT [23, 24].
However, the methods described above can only provide
indirect evidence of increased permeability resulting
from BBB disruption. They cannot provide quantifica-
tion data and require highly experienced evaluators for
correct interpretation [23]. Using the DCE-MR to quan-
titatively evaluate the BBB, the Ktrans has proved to be
the most sensitive imaging marker for the prediction of
early (within 2–3 h) fibrin leakage in the brain tissue
[24]. Kassner et al. added the DCE sequence in the con-
ventional MR of 33 patients within 4 h of the onset of
acute cerebral infarction and found progressive increase
in the BBBP in the acute phase of nine patients (five pa-
tients received tPA thrombolytic therapy), all of whom
presented with HT within 48 h [25]. However, due to
the long scan time of the DCE-MR, its application in the
ultra-early stage of acute cerebral infarction is limited.
Thus, some studies obtained BBBP values from first-pass
perfusion CT (PCT) data. For example, Wintermark and
Lee et al. applied different mathematical models to
measure the absolute values of BBBP and proposed that
the increase in the BBBP can be utilized to predict HT
[26]. Permeability imaging can systematically assess BBB
integrity and make personalized predictions regarding
the risk of hemorrhage in patients with acute ischemic
stroke, which should help realize the transformation
from the "time-window" to the "tissue-window" ap-
proach. Thus, patients who have a high risk of HT with
active treatments even within the 4.5-h therapeutic time
window, as well as those who have a relatively low risk
of HT and relatively good prognosis even beyond the
4.5-h window, can be screened out. That is, it will be
possible to move away from the fixed time-window
treatment model and develop more rational therapies
based on the evaluation of individualized risks [27].
The intracranial collateral circulation plays a critical
role in the occurrence, development, treatment, and
prognosis of ischemic stroke. The collateral circulation
is capable of maintaining perfusion and stabilizing cere-
bral blood flow, which in turn, determines the tissue
outcomes. Studies have reported that, in the patients
with severe carotid artery stenosis, a good collateral cir-
culation could reduce the incidence of long-term stroke,
perioperative risk, and transient ischemic attack [28, 29].
Regardless of the success of recanalization of occluded
vessels after thrombolytic therapy, the long-term prog-
nosis of patients with leptomeningeal collateral vessels is
better than that of other patients [30].
Methods for assessing intracranial collaterals include
transcranial Doppler (TCD) ultrasound, computed tomog-
raphy angiography (CTA), MR angiography (MRA), and
digital subtraction angiography (DSA), each of which has
its own advantages and disadvantages. For the assessment
of secondary collaterals, permeability imaging has suffi-
cient theoretical basis. The dynamic contrast-enhanced se-
quence itself contains perfusion information. In a study
on the assessment of the collateral circulation in patients
with acute stroke, Chen et al. [30] used first-pass data of
perfusion images to obtain the permeability parameter
Ktrans map, and found that the Ktrans map can assess col-
lateral circulation in the acute ischemic state. The corre-
sponding collateral circulation score is most consistent
with that of DSA. Chen et al. also found that the Ktrans
map can predict clinical outcomes after stroke.
Ktrans, as well as measurements from other sequences
in MR, also confirmed the location and the size of the
area of revascularization and angiogenesis [31]. Similar
to its usefulness in detecting tumor angiogenesis, Ktrans
is a sensitive parameter for the detection of early brain
angiogenesis in post-stroke patients. Although previous
research on the detection of angiogenesis by DCE-MR
had only revealed that increased intensity of the Ktrans
signal corresponds to increased density of newborn ves-
sels, it was not clear whether secondary and tertiary
cerebral collaterals could be evaluated through the as-
sessment of angiogenesis. In a recent study, Chen et al.
[32] collected 21 patients with severe intracranial arterial
stenosis or occlusion caused by chronic artery athero-
sclerosis. The patients all presented with severe stenosis
or occlusion of the middle cerebral artery and the intra-
cranial segment of the internal carotid artery. The study
used the corrected Alberta Stroke Program Early CT
Score (ASPECTS) segmentation standard to evaluate
collateral circulations in each of the vasculature seg-
ments and used Ktrans maps, Arterial Spin Labeling
(ASL), CTA, and DSA to score collaterals. The authors
found good agreement between the DSA and Ktrans map,
especially in the assessment of the meningeal collateral
circulation. The agreement between the CTA-source
image (CTA-SI) and DSA was moderate, while the
agreement between the ASL and DSA was the least fa-
vorable. However, the sample size in this study was too
small to draw definite conclusions.
Although Ktrans has been applied in cancer patients
[33], it is rarely used in stroke patients. This may be due
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to the lack of awareness regarding the usefulness of
Ktrans measurements. Between perfusion imaging and
permeability imaging, physicians usually prefer the
former. In fact, permeability imaging itself already con-
tains perfusion information. With optimization of the
software, a good perfusion sequence can also be ob-
tained during permeability imaging.
Application in hemorrhagic stroke
Hypertensive ICH is the deadliest and most disabling
form of stroke and affects nearly a million people world-
wide each year [34]. Studies using animal models have
shown that the toxic effects of hemoglobin degradation
products can cause increases in the BBB permeability
and lead to the formation of edema around the
hematoma [35]. Studies have speculated that disruption
of the BBB can lead to angiogenesis in the vicinity of the
hematoma, which further promotes the formation of
vasogenic edema [36]. Therefore, BBB disruption may be
an important pathophysiological factor involved in
hypertensive ICH–induced brain damage, and is a po-
tential target for therapeutic intervention [35].
The study by Didem et al. showed that the DCE-MR
could demonstrate an increase in BBB permeability in
the boundary region of the hematoma 8 days after cere-
bral hemorrhage. However, no contrast agent was found
in the hematoma itself, and BBBP was not increased in
the contralateral hemisphere [37]. Research on spontan-
eous ICH in humans has shown that contrast enhance-
ment can be observed around the hematoma in 60 % of
patients 5 days after the occurrence of the ICH [38]. No
contrast enhancement can be found in the hematoma it-
self, possibly due to blood clots preventing the leakage
of contrast agents. In an ICH rat model, Yang et al. ob-
served increased BBB permeability both in the core and
at the edge of the hematoma 7 days after the ICH [36].
However, their ICH model was created by direct injec-
tion of autologous blood instead of blood vessel rupture
and can therefore not reflect the real pathophysiological
changes of ICH in humans.
A study by Didem et al. revealed the relationship be-
tween BBB leakage and the size of the hematoma using
DCE-MR. BBB leakage is more severe around large he-
matomas (i.e., ≥30 mL), and a higher increase in the
BBBP, as well as its variability, occurred more often in
larger hematomas than in smaller ones [37]. This is con-
sistent with the observation that edema volume in bigger
hematomas is greater than that in smaller hematomas
[39]. BBB leakage varies depending on hemorrhage loca-
tion. Regardless of the size of the hematoma, BBB per-
meability and variability is higher in lobar than in deep
hemorrhages [37].
Animal studies have indicated that the BBB permeabil-
ity starts to increase only hours after ICH, and continues
until 48–72 h [36]. In these models, the amount of BBB
leakage gradually declined after the peak, which oc-
curred in the first few days after the onset of ICH. How-
ever, the increase in BBBP was sustained for up to
14 days [36]. One animal study found that the measure-
ments of the BBBP were similar between 1 week and 1-
day post-ICH [40].
Taken together, the evidence suggests that quantitative
measurements of BBB disruption by the DCE-MR can
reveal the severity of ICH-induced brain damage, and
that the technique has the potential to be used for test-
ing the efficacy of interventions aimed at reducing tissue
damage around the hematoma [37].
Application in cerebral small vessel disease
Cerebral small vessel disease can cause dementia and
stroke. The most characteristic imaging manifestations
include lacunar infarction [41], leukoaraiosis, enlarged
perivascular spaces, and cerebral microbleeds [42]. Stud-
ies have demonstrated that endothelial injuries can cause
BBB leakage at multiple sites, which leads to ongoing
damage of the vessel wall and eventually to blood vessel
ruptures and microbleeds [43]. These microbleeds to-
gether with reactive small-vessel occlusions induce cystic
infarcts of the surrounding parenchyma. Schreiber et al.
reported that in spontaneously hypertensive stroke-
prone rats, the vascular system reacts with an activated
coagulation state after the early endothelial injuries and
induces stasis formation and the accumulation of eryth-
rocytes, which represent the earliest detectable histo-
logical characteristics of small vessel disease [43].
Many studies have reported that increased BBB per-
meability occurs in the aging brain, dementia, and leu-
koaraiosis in humans. However, it must be noted that
the sample size of the study on leukoaraiosis was small
and the results are unreliable [44]. Most of the studies
examined the BBBP using biochemical methods, such
as measurement of the cerebrospinal fluid (CSF)
albumin/serum albumin ratio. Several studies have
used imaging techniques to examine the BBB, mostly
through intravenous injection of the MR contrast
agent gadolinium, a relatively nonspecific marker for
detection of the BBB disruption [44]. Topakian et al.
studied 24 patients with lacunar infarction and com-
pared them with controls. They found that in leu-
koaraiosis patients, DCE-MR revealed increased BBBP
even in regions of the white matter that appeared
normal [3]. Rosenberg et al. studied patients with vas-
cular cognitive impairment and confirmed the disrup-
tion of the BBB in the areas of leukoaraiosis [45].
Overall, BBB integrity deteriorates slowly with aging,
with the decline being more severe in patients with de-
mentia and small vessel disease. BBB damage plays an
important role in lacunar infarction, leukoaraiosis, other
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brain small vessel diseases, and age-related diseases
(such as Alzheimer disease). Preliminary reports suggest
that the BBB defect is present even before the clinical
and imaging manifestations arise. The enlarged perivas-
cular space is an important marker for cerebral small
vessel disease, and brain damage caused by inflammation
and other pathological processes is a marker for the ini-
tial damage to the BBB [12].
Long-term follow-up studies are required to determine
the role of BBB damage in the pathology of cerebral
small vessel disease. The BBB can be quantitatively eval-
uated by DCE-MR, which can be combined with path-
ology methods to identify the major mechanisms of BBB
damage and further explore its pathogenesis. Currently,
DCE-MR is mostly applied for the assessment of tumors
in patients. There is less research focused on the evalu-
ation of mild BBB defects in normal or abnormal aging
brains, dementia, or cerebral small vessel disease. More
work needs to be done to select the appropriate contrast
agents and decide their doses, as well as to identify
methods for parameter collection and data analysis [46].
Conclusions
This review discusses the applications of DCE-MR-based
permeability imaging techniques in cerebrovascular dis-
eases. With regard to the methods, T1-weighted DCE-
MR is more developed. However, due to the lack of a
unified standard for the image acquisition, data models,
and study reports, it is difficult to compare and analyze
DCE data between different studies. Further improve-
ments for enhancing the reliability and stability of the
DCE-MR are needed for its application in the assess-
ment of subtle changes in the permeability of the BBB.
Future research should attempt to establish a unified
data collection and analysis method, which should help
improve the comparability between studies and promote
the wide application of DCE-MR in clinical practice and
research [46].
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